FDA Investigator Nicole M Bell

Nicole M Bell has inspections in 6 countries as of 22 Sep 2023. Nicole M Bell has collaborated with a combinined 2552 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
Last Inspection Date:
22 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
United States of America, Slovakia, India, Canada, Serbia, Ecuador
Aaron F Coleman, Abraham M Maekele, Adam J Taylor, Adam R Cooke, Albert A Salvador, Alexander M Kay, Althea A Williams, Ana C Lazo, Ana P Barido, Angela F Orozco, Ann B Borromeo, Anne E Johnson, Anthony J Grace, Babatunde D Babalola, Barbara M Frazier, Benita C Okeke, Betsy C Galliher, Bonita S Chester, Brandy D Brown, Brittny C Cargo, Carrie L Doupnik, CDR Ileana Barreto Pettit, CDR Thomas R Berry, PPh, Christopher T Smith, Clara E Santiago, Claudele S Razo, Conner N Mann, Craig A Garmendia, Cynthia F Kleppinger, MD, Dana M Klimavicz, Daniel L Aisen, David J Leray, David P King, Dawn C Olenjack, Dawn M Mccabe, Deborah A Greco, Devaughn Edwards, Diana L Kelsch, Diana Ramirez, Diane L Kelsch, Dianiris C Ayala, Dionne D Arline, Donna D Gallien, MPH, Dr. Koffi A Amegadje, Earl Echon, Eduardo Carbonell, Edwards, Edwin J Gorney, Eileen J Bannerman, Ernest H Blackwood, Esra Toussaint, Gabriel E Muniz, Gail L Katz, German Rivera, Gina C Chen, Gloria J Baca, MS, Hugh M Mcclure, II, Hunt, Ingrid A Zambrana, Israel Juarbe, James To Neal, Jason P Aun, Jawaid Hamid, Jennifer L Huntington, Jennifer M Menendez, Joanne E King, Joel D Martinez, John D Lloyd, John J Bernal, Jose Perez Soto, Karen L Anderson, Karen M Cooper, Karen M Rodriguez, Kassa Ayalew, MD, Kathleen V Ferguson, Kelly M Byers, Kendra A Biddick, Lareese K Thomas, Laura E Garcia, Laura L Staples, Laura M Lopez, LCDR Angelica M Chica, LCDR Randall L Morris, Leon L Crawley, Leyden Guerrero, Liliya V Bubiy, Lissette Paiz, Lori A Gioia, Lundy H Patrick, Luz I Collado, Marcia A Worley, Maria D Jiron, Marinee Flores Marrero, Mark V Preciados, Mark W Rivero, Megan K Otero, Merril E Racke, Michael C Lombardi, Michael F Skelly, PhD, Michelle D Haamid, Mohsen Rajabi Abhari, FDA, Munoz, Myla D Chapman, Nancy E Fontaine, Navid R Homayouni, Nicola M Fenty Stewart, Nyvia R Burgos, Omayra Nrodriguez Ruiz, Ormond, Paul W Moy, Perry H Gambrell, Rachel A Peters, Ramon H Pabon Aponte, Randy L Clarida, Rina Bhikha, Robert Sharpnack, Robert W Calais, Roy R Rinc, Ruben C Ayala, PharmD, Ruth A Williams, Sally Gopaul, Scott B Laufenberg, Seneca D Toms, Sereen Gmorgan Murray, Sergio E Delgado, Sharon Giamberini, Shavon L Square, Sheila P Barthelemy, Sheri S Oliver, Sonya M Edmonds, Sophia A Sands, Stacey A Meyer, Stacey F Allard, Stacey L Witherwax, State Agency, Stefanie R Cook, Stephanie E Hubbard, Sunitha K Rajaram, PhD, Thea C Grome, Timothy C Grome, Toby L Keaton, Tracy R Ball, Trang N Cox, Vanessa E Coulter, Victor Spanioli, Viviana Matta, William P Tonkins, Young M Choi, PhD

Nicole M Bell's Documents

Publish Date Document Type Title
April, 2009 EIR Newpharma, Inc. - EIR, 2009-04-15
April, 2012 FDA 483 N. C. State University Research Administration - Form 483, 2012-04-19
May, 2017 EIR Recknor, Christopher M.D. - EIR, 2017-05-01
February, 2016 EIR Wake Forest University Health Sciences IRB - EIR, 2016-02-10
September, 2012 FDA 483 Ivan Bunganic - Form 483, 2012-09-28
January, 2014 EIR Jeffrey Kingsley, D.O. - EIR, 2014-01-24
July, 2015 EIR Regional Medical Center of Orangeburg & Calhoun Counties IRB - EIR, 2015-07-22
February, 2014 FDA 483 Jeffrey Kingsley, D.O. - Form 483, 2014-02-28
July, 2015 FDA 483 Alan Miller, M.D. - Form 483, 2015-07-15
August, 2012 EIR Experimental Pathology Labs - EIR, 2012-08-14
January, 2011 EIR Teva Branded Pharmaceutical Products R & D, Inc. - EIR, 2011-01-27
August, 2013 EIR Michele Sewell - EIR, 2013-08-19
January, 2013 FDA 483 TRS Labs Inc. - Form 483, 2013-01-23
July, 2015 EIR Chiltern International Inc - EIR, 2015-07-31
January, 2013 EIR TRS Labs Inc. - EIR, 2013-01-23
July, 2012 FDA 483 TRS Labs Inc. - Form 483, 2012-07-06
May, 2017 EIR Quintiles IMS - EIR, 2017-05-19
February, 2012 FDA 483 Kobrynski, Lisa - Form 483, 2012-02-10
September, 2012 FDA 483 Dragana Obradovic, MD - Form 483, 2012-09-21
July, 2012 EIR TRS Labs Inc. - EIR, 2012-07-06
January, 2016 EIR East Carolina University IRB - EIR, 2016-01-28
March, 2013 EIR WIL Research - EIR, 2013-03-07
February, 2016 FDA 483 Wake Forest University Health Sciences IRB - Form 483, 2016-02-10
January, 2012 FDA 483 Sagar Lonial, M.D. - Form 483, 2012-01-23
March, 2013 FDA 483 WIL Research - Form 483, 2013-03-07
February, 2014 EIR Jeffrey Kingsley, D.O. - EIR, 2014-02-28
December, 2012 EIR GlaxoSmithKline - EIR, 2012-12-19
January, 2014 FDA 483 Jeffrey Kingsley, D.O. - Form 483, 2014-01-24
May, 2017 FDA 483 Response Recknor, Christopher M.D. - Form 483R, 2017-05-11
February, 2012 EIR Kobrynski, Lisa - EIR, 2012-02-10
July, 2015 FDA 483 Regional Medical Center of Orangeburg & Calhoun Counties IRB - Form 483, 2015-07-22
March, 2011 FDA 483 Angelo Gousse - Form 483, 2011-03-30
March, 2013 EIR Research Triangle Institute - EIR, 2013-03-06
August, 2012 EIR GlaxoSmithKline - EIR, 2012-08-09
August, 2013 FDA 483 Michele Sewell - Form 483, 2013-08-19
November, 2015 EIR Charles River Laboratories - EIR, 2015-11-03
April, 2016 EIR Kathryn Lucas, M.D. - EIR, 2023-08-09
April, 2016 FDA 483 Kathryn Lucas, M.D. - Form 483, 2016-04-08

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

Talk to sales to access our investigator profiles


Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more